NYSE accepts Annovis Bio's plan to regain listing compliance; 18-month cure period

Annovis Bio, Inc.

Annovis received NYSE acceptance of its plan to regain compliance with minimum market capitalization and stockholders' equity standards.
NYSE granted an 18-month period from March 26, 2025, to achieve compliance; stock remains listed subject to plan adherence.
Annovis must provide quarterly progress updates to NYSE; business operations and SEC reporting unaffected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.